GeneHealth - Your precision medicine

Dhcr7-related Disorder

Disease Details

Family Health Simplified

Buy Membership

Description: A DHCR7-related disorder is a genetic condition resulting from mutations in the DHCR7 gene, leading to issues with cholesterol synthesis.

One-sentence description:
DHCR7-related disorder is a genetic condition resulting from mutations in the DHCR7 gene, impairing cholesterol synthesis and leading to developmental and physical abnormalities.
Type: The type of disorder related to DHCR7 mutations is Smith-Lemli-Opitz syndrome (SLOS). The type of genetic transmission for SLOS is autosomal recessive.
Signs And Symptoms: For DHCR7-related disorder, specifically Smith-Lemli-Opitz syndrome (SLOS), here are the signs and symptoms:

1. **Facial Features**: Microcephaly, broad nasal bridge, upturned nose, epicanthal folds, and ptosis.
2. **Skeletal Abnormalities**: Polydactyly (extra fingers or toes), syndactyly (webbing of fingers or toes), and limb abnormalities.
3. **Genital Abnormalities**: In males, hypospadias and cryptorchidism; in females, the clitoral hypertrophy.
4. **Developmental Delays**: Intellectual disability, speech and language delays, and motor skill delays.
5. **Behavioral Issues**: Hyperactivity, autistic behaviors, and self-injury.
6. **Growth Problems**: Failure to thrive, feeding difficulties, and short stature.
7. **Internal Anomalies**: Congenital heart defects, kidney abnormalities, and gastrointestinal issues.

Note: "nan" appears to be a miscommunication; no relevant details are provided for it.
Prognosis: DHCR7-related disorder, also known as Smith-Lemli-Opitz syndrome (SLOS), varies widely in prognosis depending on the severity of the condition. Generally, individuals with milder forms of the disorder may live into adulthood with varying degrees of intellectual disability and physical abnormalities. However, those with severe forms often face significant medical challenges and may have a reduced life expectancy. Early diagnosis and multidisciplinary management, including dietary modifications and supportive therapies, can improve quality of life and outcomes.
Onset: DHCR7-related disorders, such as Smith-Lemli-Opitz syndrome, typically have their onset in infancy or early childhood. Symptoms and developmental delays may be evident soon after birth.
Prevalence: DHCR7-related disorder, more commonly known as Smith-Lemli-Opitz syndrome (SLOS), has a prevalence of approximately 1 in 20,000 to 1 in 60,000 live births.
Epidemiology: DHCR7-related disorder, also known as Smith-Lemli-Opitz syndrome (SLOS), is a rare genetic disorder. Its prevalence is estimated to be about 1 in 20,000 to 1 in 60,000 live births in populations of European descent. It is less commonly reported in other populations, reflective of differences in genetic background and diagnostic practices.
Intractability: DHCR7-related disorder, such as Smith-Lemli-Opitz syndrome (SLOS), is considered intractable as there is currently no cure. Management focuses on treating symptoms, including dietary cholesterol supplementation and addressing developmental and physical abnormalities. Progress varies widely among individuals, but supportive care can improve quality of life.
Disease Severity: DHCR7-related disorder, primarily known as Smith-Lemli-Opitz syndrome (SLOS), varies in severity. The disease can range from mild to severe, depending on the extent of cholesterol biosynthesis impairment.

- Mild forms may involve minor physical anomalies and learning disabilities.
- Severe forms can present with significant intellectual disability, multiple congenital anomalies, and severe physical malformations potentially leading to life-threatening complications.
Pathophysiology: DHCR7-related disorder, commonly known as Smith-Lemli-Opitz syndrome (SLOS), is caused by mutations in the DHCR7 gene, which encodes the enzyme 7-dehydrocholesterol reductase. This enzyme is essential in the cholesterol biosynthesis pathway, specifically converting 7-dehydrocholesterol to cholesterol.

**Pathophysiology:**
1. **Enzyme Deficiency**: Mutations in DHCR7 reduce or eliminate the activity of 7-dehydrocholesterol reductase.
2. **Cholesterol Deficiency**: The reduced enzyme activity leads to a deficiency in cholesterol, which is crucial for normal cell membrane structure, function, and signaling.
3. **Accumulation of 7-dehydrocholesterol**: Unconverted 7-dehydrocholesterol accumulates in tissues and blood, contributing to toxic effects.
4. **Developmental Impact**: Cholesterol is vital for the development and function of the central nervous system, endocrine system, and the synthesis of steroid hormones and vitamin D. Deficiency and accumulation of metabolic intermediates lead to a wide range of developmental abnormalities and intellectual disabilities.

Patients with SLOS display a spectrum of symptoms, including facial anomalies, growth retardation, intellectual disability, and various structural organ defects. The severity of symptoms can vary significantly depending on the degree of enzyme deficiency.
Carrier Status: Carrier status for a DHCR7-related disorder, such as Smith-Lemli-Opitz syndrome (SLOS), typically means the individual has one mutated copy of the DHCR7 gene and one normal copy. Carriers usually do not exhibit symptoms of the disorder but can pass the mutated gene to their offspring. If both parents are carriers, there is a 25% chance with each pregnancy that their child will have SLOS, a 50% chance the child will be a carrier, and a 25% chance the child will inherit two normal copies of the gene.
Mechanism: DHCR7-related disorder, also known as Smith-Lemli-Opitz syndrome (SLOS), is caused by mutations in the DHCR7 gene, which encodes the enzyme 7-dehydrocholesterol reductase. This enzyme is crucial in the cholesterol biosynthesis pathway, specifically in the conversion of 7-dehydrocholesterol (7-DHC) to cholesterol.

**Mechanism:**
The DHCR7 gene mutations lead to a deficient or dysfunctional 7-dehydrocholesterol reductase enzyme. This impairment results in the accumulation of 7-DHC and a corresponding deficiency of cholesterol. Cholesterol is essential for various cellular functions, including cell membrane integrity, steroid hormone production, and myelination in the nervous system.

**Molecular Mechanisms:**
1. **Enzyme Deficiency:** Mutations in DHCR7 reduce the activity of 7-dehydrocholesterol reductase, diminishing the conversion rate of 7-DHC to cholesterol.
2. **7-DHC Accumulation:** The defective enzyme causes 7-DHC to accumulate in tissues and blood, as it cannot be efficiently converted to cholesterol.
3. **Cholesterol Deficiency:** Lower levels of cholesterol disrupt various biological processes, affecting the development and function of multiple systems in the body.
4. **Pathway Disruption:** The disruption of cholesterol biosynthesis impacts cellular signaling, membrane composition, and the synthesis of molecules derived from cholesterol, such as steroid hormones and bile acids.

These molecular mechanisms lead to the clinical manifestations seen in SLOS, which include developmental abnormalities, intellectual disability, and morphological defects.
Treatment: Treatment for DHCR7-related disorder, commonly known as Smith-Lemli-Opitz Syndrome (SLOS), primarily focuses on managing symptoms and improving quality of life. Key approaches include:

1. **Cholesterol Supplementation:** Oral cholesterol supplements can help address the deficiency caused by the disorder.
2. **Dietary Modifications:** Special diets low in phytosterols may be recommended.
3. **Symptomatic Treatment:** This can involve surgeries for congenital anomalies, behavioral therapies, and physical therapies.
4. **Genetic Counseling:** For affected families, to understand the inheritance and risks for future pregnancies.
5. **Monitoring and Support:** Regular follow-up with specialists in genetics, endocrinology, and other relevant fields.

There is no cure, so treatments are tailored to individual needs and symptoms.
Compassionate Use Treatment: DHCR7-related disorder, commonly known as Smith-Lemli-Opitz Syndrome (SLOS), is a congenital condition characterized by multiple developmental and health issues. Currently, there is no cure, but several experimental and compassionate use treatments are being explored:

1. **Cholesterol Supplementation:** Since SLOS is caused by impaired cholesterol synthesis, supplemental dietary cholesterol is often used to increase plasma cholesterol levels. This can help alleviate some symptoms, though the effectiveness varies among individuals.

2. **Simvastatin:** An HMG-CoA reductase inhibitor usually prescribed for high cholesterol, simvastatin has been explored off-label for SLOS to potentially reduce toxic sterol precursors.

3. **Antioxidants:** Experimental use of antioxidants such as Coenzyme Q10 and Vitamin E is based on trying to reduce oxidative stress, which is thought to play a role in the pathology.

4. **Developmental and Behavioral Therapies:** While not strictly pharmaceutical, early intervention, physical therapy, and behavioral therapy are critical components of managing SLOS symptoms and improving quality of life.

5. **Investigational Drugs:** Clinical trials and research are ongoing for new treatments targeting the biochemical pathways affected in SLOS. Interested families should consult with a specialist to explore available trials.

Patients should discuss all potential treatments with healthcare providers to understand the risks and benefits.
Lifestyle Recommendations: For individuals with DHCR7-related disorder, particularly Smith-Lemli-Opitz syndrome (SLOS), lifestyle recommendations generally focus on managing symptoms and improving quality of life. These may include:

1. **Nutritional Support**: A diet supplemented with cholesterol may help improve symptoms, as individuals with SLOS often have cholesterol deficiency.

2. **Regular Monitoring**: Routine medical check-ups to monitor growth, developmental progress, and overall health.

3. **Developmental Therapy**: Early intervention services, including physical, occupational, and speech therapy, to support developmental milestones.

4. **Avoiding Sunlight**: Care should be taken to protect the skin from sunlight, as some individuals may have increased sensitivity.

5. **Medication Management**: Prescription of medications to manage behavioral issues, sleep disturbances, and other medical conditions as needed.

6. **Education and Support**: Specialized educational plans and support systems for learning and social development.

7. **Genetic Counseling**: Advising family members about the genetic aspects of the disorder for future family planning.

Close collaboration with healthcare providers is key to optimize the management of the condition.
Medication: For DHCR7-related disorder, such as Smith-Lemli-Opitz syndrome (SLOS), there are no specific medications that cure the condition. Treatment is tailored to managing symptoms and may involve dietary cholesterol supplementation to help address the cholesterol deficiency caused by the DHCR7 gene mutation. Additionally, supportive therapies such as physical therapy, occupational therapy, and speech therapy may be beneficial. Regular monitoring and a multidisciplinary approach are important for managing the various aspects of the disorder.
Repurposable Drugs: DHCR7-related disorder, commonly known as Smith-Lemli-Opitz syndrome (SLOS), is a genetic condition characterized by mutations in the DHCR7 gene, which result in defective cholesterol synthesis. There are several potential repurposable drugs and treatments that are being explored to manage this disorder:

1. **Cholesterol Supplementation**: Given the deficiency in cholesterol, supplementing with dietary cholesterol is a primary therapeutic approach.

2. **Simvastatin**: This statin drug can potentially increase the levels of some cholesterol precursors and reduce toxic by-products. It might also have anti-inflammatory benefits.

3. **HMG-CoA Reductase Inhibitors**: Similar to simvastatin, other statins might be explored for their effects on cholesterol metabolism.

It is important for these treatments to be tailored to the individual needs of patients, and they should be managed and monitored by healthcare professionals.
Metabolites: DHCR7-related disorder, also known as Smith-Lemli-Opitz syndrome (SLOS), is characterized by abnormalities in cholesterol synthesis due to mutations in the DHCR7 gene. This condition leads to an accumulation of 7-dehydrocholesterol (7-DHC), which is a metabolic precursor to cholesterol. Consequently, there is a deficiency in cholesterol levels.

Metabolites associated with DHCR7-related disorder include:
- Elevated levels of 7-dehydrocholesterol (7-DHC)
- Elevated levels of 8-dehydrocholesterol (8-DHC)
- Reduced levels of cholesterol

These metabolic abnormalities are used as diagnostic markers for the disorder.
Nutraceuticals: DHCR7-related disorder, commonly known as Smith-Lemli-Opitz syndrome (SLOS), is a genetic condition caused by mutations in the DHCR7 gene leading to defective cholesterol synthesis. Nutraceuticals, specifically supplemental cholesterol, are sometimes used in the management of this disorder. Cholesterol supplementation can help improve various symptoms, although it does not completely normalize biochemical abnormalities or prevent developmental delays. Nonetheless, it represents an important part of the therapeutic strategy for managing SLOS.
Peptides: DHCR7-related disorder, also known as Smith-Lemli-Opitz syndrome (SLOS), is a rare genetic condition caused by mutations in the DHCR7 gene. This gene plays a crucial role in cholesterol biosynthesis by coding for the enzyme 7-dehydrocholesterol reductase. Peptides, specifically signaling peptides or therapeutic peptides, have not been established as standard treatments for this disorder. Instead, current management typically includes dietary cholesterol supplementation and symptomatic treatment to address physical and developmental abnormalities. Research in novel therapeutic approaches such as gene therapy is ongoing but not yet standard practice.